Roche Holding AG (LTS:0QOK)
CHF 248.4 1.25 (0.51%) Market Cap: 201.45 Bil Enterprise Value: 231.01 Bil PE Ratio: 18.78 PB Ratio: 6.84 GF Score: 84/100

Roche Holding AG Virtual EHA 2023 Event: Crovalimab in Hematology and Nephrology Transcript

Jun 12, 2023 / 02:30PM GMT
Release Date Price: CHF283.53 (-0.29%)
Operator

(Operator Instructions) One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to roche.com/investors to download the presentation.

At this time, it's my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.

Bruno Eschli
Roche Holding AG - Head of IR

Thanks a lot, Henry. And can I have the first slide, please?

So welcome to our third IR call in 2023, this time focusing on crovalimab. The crovalimab development program, especially on PNH, the results presented at EHA and also on our emerging nephrology franchise. And let me quickly make an upfront statement here. I think the nephrology franchise, which today already consists of 4 medicines, we'll have a first major readout to come next year in 2024, with Gazyva and lupus nephritis. And based on the very strong Phase II results, this indication also got a breakthrough therapy designation. So the overall opportunity, which we flagged here for Gazyva in lupus nephritis in SLE in membranous

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot